Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Emerging Targets in Immunotherapy

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 3 of 3
OX40 agonists: Past, present, and future
Andrew D Weinberg
Robert W. Franz Cancer Research Center, Portland, OR, United States
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-2:45 PM
Preclinical assessment of JTX-2011, an agonist antibody targeting ICOS, supports evaluation in ICONIC clinical trial
Jennifer S. Michaelson
Jounce Therapeutics, Cambridge, MA, United States
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-2:45 PM
Isotype choice for antibody immunotherapy: Lessons from engineering anti-CD73 and anti-TIGIT therapeutic antibodies
Bryan C. Barnhart
Bristol-Myers Squibb Co., Redwood City, CA, United States
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-2:45 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 3 of 3